INTRODUCTION: Since the outcomes associated with the use of renin-angiotensin-system inhibitors (RASi) by hemodialysis (HD) patients are not fully known, we investigated their effect on the cardiovascular mortality of chronic HD patients. METHODS: Data from 388 HD patients (237 men and 151 women) who were routinely treated for at least 6 months were analyzed. Treatment with a RASi was the major predictor variable. The main outcome measure was cardiovascular mortality. Cox regression analysis was used to assess for the use of RASi and risk of death. RESULTS: Hypertension was diagnosed in 320 patients (82.5%), and 197 (50.8%) of them were treated with a RASi (treated group) and 191 (49.2%) were not (untreated group). The treated group had a higher prevalence of hypertension, history of congestive heart failure, and presence of ST-T changes. Kaplan-Meier analysis revealed a reduction in risk of cardiovascular death in the treated group during the follow-up period (fig. 2; log-rank: p=0.0379). The multivariate analysis showed that treatment with a RASi was also independently associated with reduced cardiovascular mortality (hazard ratio= 0.184; p=0.0161). CONCLUSIONS: The results of this study suggest a possible association between the treatment with RASi and reduced risk of cardiovascular mortality, independent of their effect of lowering blood pressure.
[1] E. Villar, L. Remontet, M. Labeeuw and R. Ecochard, “Effect of Age, Gender, and Diabetes on Excess Death in End-Stage Renal Failure,” Journal of American Society of Nephrology, Vol. 18, No. 7, 2007, pp. 2125-2134. doi:10.1681/ASN.2006091048
[2] R. N. Foley, A. M. Murray, S. Li, et al., “Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998-1999,” Journal of American Society of Nephrology, Vol. 16, No. 2, 2005, pp. 489-495. doi:10.1681/ASN.2004030203
[3] A. J. Collins, “Cardiovascular Mortality in End-Stage Renal Disease,” American Journal of Medical Science, Vol. 325, No. 4, 2003, pp.163-167. doi:10.1097/00000441-200304000-00002
[4] R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray and P. E. Barre, “Impact of Hypertension on Cardiomyopathy, Morbidity and Mortality in End-Stage Renal Disease,” Kidney International, Vol. 49, No. 5, 1996, pp. 1379-1385. doi:10.1038/ki.1996.194
[5] P. G. Zager, J. Nikolic, R. H. Brown, et al., ” “U” Curve Association of Blood Pressure and Mortality in Hemodialysis Patients,” Kidney International, Vol. 54, No. 2, 1998, pp. 561-569. doi:10.1046/j.1523-1755.1998.00005.x
[6] F. K. Port, T. E. Hulbert-Shearon, R. A. Wolfe, et al., “ Predialysis Blood Pressure and Mortality Risk in a National Sample of Maintenance Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 33, No. 3, 1999, pp. 507-517. doi:10.1016/S0272-6386(99)70188-5
[7] K. Kakantar-Zadeh, R. D. Kilpatrick, C. J. McAllister, S. Greenland and J. D. Kopple, “Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: the 58th Annual Fall Conference and Scientific Sessions,” Hypertension Vol. 45, No. 4, 2005, pp. 811-817. doi:10.1161/01.HYP.0000154895.18269.67
[8] R. Agarwal, “Hypertension and Survival in Chronic Hemodialysis Patients-Past Lessons and Future Opportunities,” Kidney International, Vol. 67, No. 1, 2005, pp. 1-13. doi:10.1111/j.1523-1755.2005.00050.x
[9] Z. Li, E. Jr. Lacson, E. G. Lowrie, et al., “The Epidemiology of Systolic Blood Pressure and Death Risk in Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 48, No. 4, 2006, pp. 606-615. doi:10.1053/j.ajkd.2006.07.005
[10] F. Zannad, M. Kessler, P. Lehert, et al., “Prevention of Cardiovascular Events in End-Stage Renal Disease: Results of a Randomized Trial of Fosinopril and Implications for Future Studies,” Kidney International, Vol. 70, No. 7, 2006, pp.1318-1324. doi:10.1038/sj.ki.5001657
[11] A. Takahashi, H. Takase, T. Toriyama, et al., “Candesartan, an Angiotensin II Type-1 Receptor Blocker, Reduces Cardiovascular Events in Patients on Chronic Haemodialysis Patients-a Randomized Study,” Nephrology Dialysis Transplantation, Vol. 21, No. 9, 2006, pp. 2507-2512. doi:10.1093/ndt/gfl293
[12] H. Suzuki, Y. Kanno, S. Sugahara, et al., “Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: an Open-Label Randomized Controlled Trial,” American Journal of Kidney Disease, Vol. 52, No. 3, 2008, pp. 501-506. doi:10.1053/j.ajkd.2008.04.031
[13] G. Cice, L. Ferrara, A. D’Andrea, et al., “Carvedilol Increases Two-Year Survivalian Dialysis Patients with Dilated Cardiomyopathy: A Prospective, Placebo-Con- trolled Trial,” Journal of American College of Cardiology, Vol. 41, No. 9, 2003, pp. 1438-1444. doi:10.1016/S0735-1097(03)00241-9
[14] M. Tepel, W. Hopfenmueller, A. Scholze, A. Maier and W. Zidek, “Effect of Amlodipine on Cardiovascular Events in Hypertensive Hemodialysis Patients,” Nephrology Dialysis Transplantation, Vol. 23, No. 11, 2008, pp. 3605-3612. doi:10.1093/ndt/gfn304
[15] P. Roy, J. Bouchard, R. Amyot and F. Madore, “Prescription Patterns of Pharmacological Agents for Left Ventricular Systolic Dysfunction among Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 48, No. 4, 2006, pp. 645-651. doi:10.1053/j.ajkd.2006.06.006
[16] W. C. Winkelmayer, R. Levin and S. Setoguchi, “Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction,” Clinical Journal of American Society of Nephrology, Vol. 3, No. 5, 2008, pp. 1415-1422. doi:10.2215/CJN.02010408
[17] R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray and P. E. Barre, “Hypoalbuminemia, Cardiac morbidity, and Mortality in End-Stage Renal Disease,” Journal of American Society of Nephrology, Vol. 7, No. 5, 1996, pp. 728-736.
[18] P. W. Macfarlane and S. Latif, “Automated Serial ECG Comparison Based on the Minnesota Code,” Journal of Electrocardiology, Vol. 29, Suppl. 1, 1996, pp. 29-34. doi:10.1016/S0022-0736(96)80016-1
[19] K. G. Alberti and P. Z. Zimmet, “Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consultation,” Diabetes Medicine, Vol. 15, No. 7, 1998, pp. 539-553. doi:10.1002/(SICI)1096-9136(199807)15:7 3.0.CO;2-S
[20] J. J. De Lima, H. Abensur, E. M. Krieger and F. Pileggi, “Arterial Blood Pressure and Left Ventricular Hypertrophy in Haemodialysis Patients,” Journal of Hypertension, Vol. 14, No. 8, 1996, pp. 1019-1024. doi:10.1097/00004872-199608000-00013
[21] H. J. Heerspink, T. Ninomiya, S. Zoungar, et al., “Effect of Lowering Blood Pressure on Cardiovascular Events and Mortality in Patients on Dialysis: a Systematic Review and Meta-Analysis,” The Lancet, Vol. 373, No. 9668, 2009, pp. 1009-1015. doi:10.1016/S0140-6736(09)60212-9
[22] R. Agarwal and A. D. Sinha, “Cardiovascular Protection with Antihypertensive Drugs in Dialysis Patients: Systematic Review and Meta-Analysis,” Hypertension, Vol. 53, No. 5, 2009, pp. 860-866. doi:10.1161/HYPERTENSIONAHA.108.128116
[23] J. M. Lopez-Gomez, M. M. Villaverde, R. Jofre, P. Rodriguez-Benitez and R. Perez-Garcia, “Interdialysis Weight gain as a Marker of Blood Pressure, Nutrition, and Survival in Hemodia1ysis Patients,” Kidney International, Vol. 93, Suppl., 2005, pp. 63-68. doi:10.1111/j.1523-1755.2005.09314.x
[24] “Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009).” Guidelines subcommittee of the Japanese Society of Hypertension. Tokyo, Japan, 2009.
[25] A. V. Chobanian, G. L. Bakris, H. R. Black, et al., “Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure,” Hypertension , Vol. 42, No. 6, 2003, pp. 1206- 1252. doi:10.1161/01.HYP.0000107251.49515.c2
[26] U. M. Khosla and R. J. Johnson, “Hypertension in the Hemodialysis Patients and the “Lag Phenomenon”: Insights into Pathophysiology and Clinical Management, American Journal of Kidney Disease, Vol. 43, No. 4, 2004, pp. 739-808. doi:10.1053/j.ajkd.2003.12.036
[27] P. Zucchelli, A. Santoro and A. Zuccala, “Genesis and Control of Hypertension in Hemodialysis Patients,” Seminar in Nephrology, Vol. 8, No. 2, 1988, pp. 163-168.
[28] P. A. McCullough, K. R. Sandberg, J. Yee and M. P. Hudson, “Mortality Benefit of Angiotensin-Converting Enzyme Inhibitors after Cardiac Events in Patients with End-Stage Renal Disease,” Journal of Renin-Angio- tensin-Aldosterone System, Vol. 3, No. 3, 2002, pp. 188-191. doi:10.3317/jraas.2002.040
[29] A. K. Berger, S. Duval and H. M. Krumholz, “Aspirin, beta-Blocker, and Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with End-Stage Renal Disease and an Acute Myocardial Infarction,” Journal of American College of Cardiology, Vol. 42, No. 2, 2003, pp. 201-208. doi:10.1016/S0735-1097(03)00572-2
[30] S. Efrati, R. Zaidenstein, V. Dishy V, et al., “ACE Inhibitors and Survival of Hemodialysis Patients,” American Journal of Kidney Disease, Vol. 40, No. 5, 2002, pp. 1023-1029. doi:10.1053/ajkd.2002.36340
[31] F. Zannad, M. Kessler, P. Lehert P, et al., “Prevention of Cardiovascular Events in End-Stage Renal Disease: Results of a Randomized Trial of Fosinopril and Implications for Future Studies,” Kidney International, Vol. 70, No. 7, 2006, pp. 1318-1324. doi:10.1038/sj.ki.5001657
[32] W. Fang, D. G. Oreopulos and J. M. Bargman, “Use of ACE Inhibitors or Angiotensin Receptor Blockers and Survival in Patients on Peritoneal Dialysis,” Nephrology Dialysis Transplantation, Vol. 23, No. 11, 2008, pp. 3704-3710. doi:10.1093/ndt/gfn321
[33] I. Kolesnyk, M. Noodzij, F. W. Dekker, E. W. Boeschoten and R. T. Krediet, “A Positive Effect of AII Inhibitors on Peritoneal Membrane Function in Long-Term PD Patients,” Nephrology Dialysis Transplantation, Vol. 24, No. 1, 2008, pp. 272-277. doi:10.1093/ndt/gfn421
[34] K. Iseki, T. Shoji, S. Nakai, et al., “Higher Survival Rates of Chronic Hemodialysis Patients on Anti-Hypertensive Drugs,” Nephron Clinical Practice, Vol. 113, No. 3, 2009, pp 183-190. doi:10.1159/000232600